Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications
Posted Jun 09 2010 5:00pm
Description of Invention: Parvovirus B19 (B19V) is the only known pathogenic human parvovirus. Infection by this viral pathogen can cause transient aplastic crisis in individuals with high red cell turnover, pure red cell aplasia in immunosuppressed patients, and hydrops fetalis during pregnancy. In children, B19V most commonly causes erythema infectiosum, or fifth's disease. Infection can also cause arthropathy and arthralgia. The virus is very erythrotropic, targeting human erythroid (red blood) progenitors found in the blood, bone marrow, and fetal liver. Currently, there are no approved vaccines or antiviral drugs for the treatment or prevention of B19V infection.
The subject technology is a series of plasmid constructs with codon optimized B19 viral capsid genes (VP1 and VP2) that can be expressed in mammalian cells. Transfection of vectors encoding these optimized VP1 and VP2 genes into different mammalian cell lines, including 293, Cos7, and Hela cells produce virus-like particles (VLPs). The vectors include bicistronic plasmids expressing the VP1 and VP2 proteins at different ratios to produce B19V VLPs with optimal antigenicity for vaccine applications. This technology can also be used for diagnostic applications and development of a viral packaging system for producing infectious B19V virus.
VLPs based vaccines for the prevention and/or treatment of B19V infection
DNA based vaccines for the prevention and/or treatment of B19V infection
Viral packaging system
Codon optimized VP1 and VP2 genes for better expression in mammalian cell lines
Expression of B19V VLPs from "nonpermissive" cell lines
Development Status: In vitro data can be provided upon request.
Inventors: Ning Zhi (NHLBI) Neal S Young (NHLBI) Sachiko Kajigaya (NHLBI)
U.S. Provisional Application No. 61/337,983 filed 12 Feb 2010
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the subject technology. Please contact Cecilia Pazman, Ph.D., at firstname.lastname@example.org for more information.
For Additional Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5018 Fax: 301-402-0220